Zevra Therapeutics (NASDAQ:ZVRA) Now Covered by Cantor Fitzgerald

Investment analysts at Cantor Fitzgerald assumed coverage on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a research report issued on Wednesday. The firm set an “overweight” rating and a $25.00 price target on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 191.38% from the company’s current price.

A number of other equities research analysts also recently weighed in on ZVRA. Guggenheim began coverage on shares of Zevra Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $20.00 price target for the company. Canaccord Genuity Group dropped their price target on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. Maxim Group increased their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Finally, JMP Securities began coverage on shares of Zevra Therapeutics in a research note on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price objective on the stock. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $21.57.

Zevra Therapeutics Stock Performance

NASDAQ:ZVRA traded up $0.34 during mid-day trading on Wednesday, hitting $8.58. 150,570 shares of the stock were exchanged, compared to its average volume of 397,903. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The firm’s 50-day simple moving average is $8.78 and its 200 day simple moving average is $7.58. Zevra Therapeutics has a fifty-two week low of $4.20 and a fifty-two week high of $9.76. The stock has a market capitalization of $457.97 million, a price-to-earnings ratio of -4.36 and a beta of 2.01.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.25). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The business had revenue of $3.70 million during the quarter, compared to analyst estimates of $5.04 million. During the same quarter last year, the company posted ($0.40) earnings per share. As a group, equities analysts anticipate that Zevra Therapeutics will post -1.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Zevra Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. MetLife Investment Management LLC increased its stake in shares of Zevra Therapeutics by 8.1% in the third quarter. MetLife Investment Management LLC now owns 22,866 shares of the company’s stock valued at $159,000 after buying an additional 1,717 shares during the period. City State Bank raised its position in shares of Zevra Therapeutics by 14.1% in the 3rd quarter. City State Bank now owns 16,224 shares of the company’s stock worth $113,000 after acquiring an additional 2,000 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Zevra Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after purchasing an additional 2,452 shares during the period. International Assets Investment Management LLC boosted its position in shares of Zevra Therapeutics by 594.0% during the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock valued at $48,000 after purchasing an additional 5,940 shares in the last quarter. Finally, IFG Advisors LLC grew its stake in Zevra Therapeutics by 41.2% during the third quarter. IFG Advisors LLC now owns 26,400 shares of the company’s stock worth $183,000 after purchasing an additional 7,700 shares during the period. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.